Apply: Rare As One RFA (Cycle 3)
CZ Biohub New York Will Build Tech To Detect Diseases Earlier
Building the Future of Science
Over the next 10 years, our north star is to understand the mysteries of the cell and how cells interact within systems, which we believe will lead to discoveries that will change medicine in the decades that follow.
Transformative medicine is most often derived from discoveries in basic science.
Understanding disease reveals fundamental human biology.
Technological advances are revolutionizing our understanding of how cells function in health and disease.
Fundamental questions in human biology often have a line of sight to medical applications, and understanding cells are important in answering those questions.
We aim to help make every scientist a better scientist by improving the tools and technologies they rely on every day. We work closely with researchers to understand their challenges and build solutions for the scientific community. Learn more about our tools.
We work in areas where we think there are deeply inspiring problems that are amenable to software innovation. We strive to make a differentiated impact through supporting technology development, interdisciplinary research collaborations, and partnerships. Learn about our work in science.
We created new scientific institutes to take on grand scientific challenges in areas such as imaging, cell biology, neuroscience, and artificial intelligence while building new technologies and tools to tackle them. Learn more about the science we do.
“By funding great science, doing the research that can’t be done in conventional environments, and building hardware and software tools for everyone, we think we can help accelerate the pace of scientific discovery.”
Meet Our Team
MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS
Asifa Akhtar is the first international female Vice President of the Biology and Medicine Section in the Max Planck Society. Born in Karachi, Pakistan, she obtained her doctorate at the Imperial Cancer Research Fund in London, UK in 1997. She then moved to Germany, where she was a Postdoctoral fellow at the European Molecular Biology Laboratory (EMBL) in Heidelberg and the Adolf-Butenandt-Institute in Munich from 1998 to 2001. She rejoined the EMBL Heidelberg as a group leader before becoming a Max Planck Investigator at the MPI in Freiburg in 2009. Since 2013, she has been a director at the MPI for Immunobiology and Epigenetics in Freiburg. Asifa Akhtar was awarded the Early Career European Life Science Organization Award in 2008, EMBO membership in 2013, and the Wilhelm-Feldberg Prize in 2017. She was elected as a member of the National Academy of Science Leopoldina in 2019.
A Pakistani biologist who has made significant contributions to the field of chromosome regulation, Asifa Akhtar’s research focus is the study of chromatin and epigenetic mechanisms. Using Drosophila melanogaster as an experimental model, Akhtar investigates how dosage compensation acts in regulation of the X chromosome. Studies have also focused on how the nuclear RNA helicase, DHX9, protects the genome from deleterious effects of transposon insertion. More recently Akhtar has investigated how transcription fidelity is affected by changes in the nucleosome landscape.
THE ROCKEFELLER UNIVERSITY
Cori Bargmann, a neurobiologist and geneticist, is Distinguished Fellow and Head of Science Emerita at the Chan Zuckerberg Initiative, and is also the Torsten N. Wiesel Professor at The Rockefeller University. Her research on the relationships between genes, motivational states, and behavior has been recognized by membership in the National Academy of Sciences and the Breakthrough Prize in Life Sciences, among other honors. Prior to joining CZI, Cori served as co-chair with Bill Newsome of the NIH working group that planned the BRAIN Initiative, and was an investigator of the Howard Hughes Medical Institute. Cori initiated the CZI Head of Science role in 2016 and will remain with CZI until the end of this year, when she will return to her lab at the Rockefeller University full-time and join CZI’s Scientific Advisory Board.
UT SOUTHWESTERN MEDICAL CENTER
Director of the Eugene McDermott Center for Human Growth and Development and a professor of internal medicine and molecular genetics at The University of Texas Southwestern Medical Center
Helen H. Hobbs, M.D., is an Investigator of the Howard Hughes Medical Institute and a Professor of Internal Medicine and Molecular Genetics at the University of Texas Southwestern Medical Center. She obtained her undergraduate degree from Stanford University prior to attending Case Western Reserve University School of Medicine. After completing an internship in internal medicine at Columbia-Presbyterian Medical Center, she moved to Dallas, Texas where she finished her clinical training and served as chief resident in internal medicine at Parkland Memorial Hospital. She worked as a postdoctoral fellow in the laboratory of Drs. Michael Brown and Joseph Goldstein before joining the faculty of UT Southwestern in 1987. She is Director of the McDermott Center for Human Growth and Development, which serves as the Center for Human Genetics at UT Southwestern. She established the Dallas Heart Study, a longitudinal, multiethnic, population-based study of Dallas County, which is now supported by the Hoffman Family Center in Genetics and Epidemiology, and by the National Center for Advancing Translational Science (NCATS). Her work focuses on defining the genetic determinants of plasma lipid levels and cardiovascular risk. Most recently, she has identified genetic variations that confer susceptibility to fatty liver disease.
More: https://utswmed.org/doctors/helen-hobbs/ https://www.hhmi.org/scientists/helen-h-hobbs https://en.wikipedia.org/wiki/Helen_Hobbs https://www.pfizer.com/people/leadership/board_of_directors/helen_hobbs-md
Michael Fischbach is an Associate Professor in the Departments of Bioengineering and Microbiology & Immunology at Stanford University, an Institute Scholar of Stanford ChEM-H, and the director of the Stanford Microbiome Therapies Initiative. Fischbach is a recipient of the NIH Director's Pioneer and New Innovator Awards, an HHMI-Simons Faculty Scholars Award, a Fellowship for Science and Engineering from the David and Lucille Packard Foundation, a Medical Research Award from the W.M. Keck Foundation, a Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease award, and a Glenn Award for Research in Biological Mechanisms of Aging. His laboratory uses a combination of genomics and chemistry to identify and characterize small molecules from microbes, with an emphasis on the human microbiome. Fischbach received his Ph.D. as a John and Fannie Hertz Foundation Fellow in chemistry from Harvard in 2007, where he studied the role of iron acquisition in bacterial pathogenesis and the biosynthesis of antibiotics. After two years as an independent fellow at Massachusetts General Hospital, Fischbach joined the faculty at UCSF, where he founded his lab before moving to Stanford in 2017. Fischbach is a co-founder and director of Federation Bio and Viralogic, a co-founder of Revolution Medicines, a member of the scientific advisory boards of NGM Biopharmaceuticals and Zymergen, and an innovation partner at The Column Group.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Jonathan S. Weissman is the Landon T. Clay Professor of Biology at the Massachusetts Institute of Technology, a member of the Whitehead Institute, and a Howard Hughes Medical Institute Investigator. From 1996 to 2020, he was a faculty member in the department of Cellular Molecular Pharmacology at the University of California, San Francisco. Jonathan Weissman investigates how proteins fold into their correct shape and how misfolding impacts disease and normal physiology, while building innovative tools for exploring the organizational principles of biological systems. The team also develops experimental and analytical approaches for exploring the organizational principles of biological systems and globally monitoring protein translation through ribosome profiling. A broad goal of his work is to bridge large-scale approaches and in depth mechanistic investigations to reveal the information encoded within genomes. Weissman has been a member of the National Academy of Sciences since 2009.
He earned his B.A. in Physics from Harvard College (1988) and his Ph.D. in Physics (1993) from MIT working with Peter Kim. There, he started his studies on protein folding examining Bovine pancreatic trypsin inhibitor (BPTI). He was a postdoctoral fellow at Yale University (1993-1996), where he worked with Arthur Horwich studying the mechanism of GroEL.
DST GLOBAL AND BREAKTHROUGH PRIZE FOUNDATION
Yuri founded Mail.ru Group in 1999 and under his leadership it became one of Europe’s leading internet companies. He took that business public in 2010 and founded DST Global to focus on global internet investments. DST Global became one of the world’s leading technology investors and its portfolio has included some of the world's most prominent internet companies, such as Facebook, Twitter, WhatsApp, Snapchat, Airbnb, Spotify, Alibaba, and others. Yuri lives in Silicon Valley with his family.
Yuri graduated in 1985 with an advanced degree in theoretical physics and subsequently conducted research in quantum field theory. Yuri and his wife Julia, partnered with Sergey Brin, Priscilla Chan and Mark Zuckerberg, Pony Ma, and Anne Wojcicki to fund the Breakthrough Prizes - the world’s largest scientific awards, honoring important, primarily recent, achievements in Fundamental Physics, Life Sciences and Mathematics. In July 2015, together with Stephen Hawking, Yuri launched the $100 million Breakthrough Listen initiative to reinvigorate the search for extraterrestrial intelligence in the Universe, and in April 2016 they launched Breakthrough Starshot - a $100 million research and engineering program seeking to develop a technology for interstellar travel.
We can’t accelerate science alone. Our Science Advisory Board informs our priorities and allows us to draw on a wide range of expertise as we shape our strategy, establish partnerships, and develop scientific projects.